VEEVVeeva Systems
$301.80-0.21%Delayed market dataLife-sciences softwareSoftware & cloud · 17 peers →Key levels and trade conditions
Delayed quotes · Technical conditionsShowing the near-term range, based on the latest 5 completed sessions and updated after each close.
Hold and monitor; no addition yet
Signals require closing-price and volume confirmation; review the company research below before acting.
When does defense take priority?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close below $294.99 → consider reducing
When to consider adding?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close above $311.38 → consider a staged addition
01Newstock overall assessment
The conclusion first, followed by the evidence that matters most.
Watch — await combined confirmation. An entry assessment has not yet been established.
02What happened recently
Company events, industry developments and market conditions — facts separated from possible explanations.
US 10Y yield 5.14%2026-11-13T18:40:14.000Z
VIX 19.472026-11-13T18:40:16.000Z
Dollar index 103.382026-11-13T18:45:17.000Z
Market and sector reference
VEEV -0.20% · SPY -0.51% · Peer average +1.38% (ADBE, ADSK, APP, CRM, DDOG, HUBS)
2026-11-13T18:55:30.000Z · Yahoo · Aligned-session reference, not a causal attribution.
Related news and impact paths
Recent news related to this stock
0 direct · 4 2nd-order · 0 thematicRanked by model assessment and recency. Labels use the original model impact, not expected returns. Impact percentages are model estimates, not observed price changes, probabilities or guaranteed returns.
- #1Impact2.4%Favorable2nd-orderOracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation25d ago
Pharma digitization of R&D and commercial workflows increases reliance on cloud-based data and compliance systems, where Veeva is deeply embedded.
Also named: ORCL · MSFT · AMZN · EPAM · DDOG · CRWD
- #2Impact1.4%Favorable2nd-orderMicrosoft's Mustafa Suleyman says its AI outperforms doctors on hard cases as he chases ‘medical superintelligence'22d ago
Pharma and life-sciences customers may be more willing to pay higher software rates for AI-assisted R&D, medical affairs and compliance workflows, reinforcing Veeva’s SaaS stickiness.
Also named: MSFT · AMZN · ORCL · GEHC · HCA · UNH
- #3Impact1.3%Favorable2nd-orderOracle stock's next big AI opportunity may have nothing to do with data centres25d ago
Drug development and commercialization software is a classic vertical AI use case, so investors may place a higher value on renewal and upsell potential across the platform.
Also named: ORCL · 赛富时 · SERVICENOW · EPAM · AMZN · MSFT
- #4Impact1.2%Adverse2nd-orderDefinitive Healthcare Reports Financial Results for Third Quarter 20268d ago
While Veeva is more core-system oriented, weaker demand for data subscriptions can still push investors toward a more conservative view on pharma IT budget growth.
Also named: DH · MDCX · IQV · EXAS
03Is the company worth considering?
Business quality, financials, valuation and analyst disagreements.
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $3.2B · latest quarter up 17.6% YoY · reported FY net income of $909M · short-sale volume share near its recent available-day average.
FY revenue
$3.2B
2026-01
Latest Q YoY
+17.6%
Gross margin
75.5%
FY net income
$909M
Diluted EPS
$5.55
Short-sale volume share
53.4%
2026-11-05 · Recent available-day avg 50.2% · near recent average
Short-sale volume as a share of trades covered by the FINRA file, not all market trading or outstanding short positions. Changes do not establish that short sellers are adding or covering positions.
🐋 Ownership filings (last 180 days)
Recent 13D/13G beneficial ownership filings, which may include amendments. A filing does not establish a recent purchase or a current holding, and its form type alone does not establish investment intent. Read the original filing for details.
- 2026-07-31SCHEDULE 13GVANGUARD CAPITAL MANAGEMENT LLC
- 2026-07-30SCHEDULE 13G/ABlackRock, Inc.
Historical results versus analyst expectations
🎯 Market expectations
Estimate context score High · 73/100Nasdaq analyst consensus · currently available data
- Jul 2026$1.68 vs $1.62+3.7%
- Apr 2026$1.59 vs $1.55+2.58%
- Jan 2026$1.50 vs $1.36+10.29%
- Oct 2025$1.42 vs $1.36+4.41%
The takeaway
EPS exceeded the corresponding consensus estimates by an average of 5.2% in the quarters shown. This is not a hurdle for the next report or a forecast of the stock's reaction.
Analyst estimates, not our forecast · not investment advice
Analyst consensus and disagreement
Target-price summary $180.00–$400.00 · Consensus $320.22
Buy / hold / sell 17 / 6 / 1
Nasdaq · Retrieved 2026-11-13T18:55:56.241Z · The aggregate does not provide individual report dates or original theses. It does not establish undervaluation; no analyst rationale is inferred. Targets are not guaranteed outcomes.
Next-quarter EPS estimate (Oct 2026) $1.68 · $1.58–$1.75 · 7 analysts
Four-week estimate revisions: up / down 0 / 0
Estimate dispersion 10.1%
Nasdaq EPS forecasts · retrieved 2026-11-13T18:55:55.132Z04Is now a good time?
Trend, moving averages, volume and key price levels — not the decline alone.
Technical structure · Mixed structure
MA5 $304.57
MA10 $306.68
MA20 $311.93
MA60 $286.62
Last completed-session close $302.42 (-0.77%) · Volume / prior 20-session average 0.52×
Prior 20-session range $294.99–$325.99 · MA20 change over five sessions +0.30% · CMF20 0.12
- Low-volume pullback within an improving structure
- Accumulation-like price/volume pattern (inference)
Confirmation to watch: a close above $325.99 with volume at least 1.5× the prior 20-session average. A heavy-volume break below $294.99 weakens the setup.
Completed daily candles only. Daily OHLCV cannot establish accumulation, shakeout or manipulation intent; CMF is a price/volume proxy, not actual fund flows. Thresholds are research rules, not validated success probabilities. Yahoo · 2026-11-12
Price and news
Historical prices and volume. Drag to pan; scroll to zoom.
Related news
05What would change our assessment?
Conditions for reconsidering entry and developments that invalidate the thesis.
Complete the company and technical cross-check before defining entry and invalidation conditions.
Additional risk evidence and model detail
Market View
Crowding
Risk temperature
Tail risk
Triggers
Price and volume
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial